The intermediate-conductance Ca2+-activated K+ channel (KCa3.1) in vascular disease

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 1, 2009, Pages 1-11

  Tharp, D L ^a   Bowles, D K ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Angioplasty; Atherosclerosis; EDHF; Endothelial cells; Intermediate conductance Ca2+ activated K+ channel; KCa3.1; Restenosis; Smooth muscle cells

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; ALPHA SMOOTH MUSCLE ACTIN; BASIC FIBROBLAST GROWTH FACTOR; BETA CYCLODEXTRIN; CETIEDEL; CHARYBDOTOXIN; CLOTRIMAZOLE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MAUROTOXIN; MYOSIN HEAVY CHAIN; NIFEDIPINE; NITRIC OXIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN; PROTEIN C FOS; PROTEIN C JUN; QUININE; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; SMOOTHELIN; TRAM 34; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; PROTECTIVE AGENT;

ANGIOGENESIS; BLOOD VESSEL TONE; CALCIUM MOBILIZATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL LEVEL; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENDOTHELIUM CELL; ERYTHROCYTE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; HUMAN; HYPERPOLARIZATION; IC 50; LIVER INJURY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; POTASSIUM CONDUCTANCE; POTASSIUM TRANSPORT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION; UPREGULATION; VASCULAR DISEASE; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; DRUG ANTAGONISM; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PROTECTIVE AGENTS; VASCULAR DISEASES;

EID: 64149096889     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509787047649     Document Type: Review

References (90)

1. Wei, A.D.; Gutman, G.A.; Aldrich, R.; Chandy, K.G.; Grissmer, S.; Wulff, H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol. Rev., 2005, 57, 463.
2. Gardos, G. The function of calcium in the potassium permeability of human erythrocytes. Biochim. Biophys. Acta, 1958, 30(3), 653.
3. + channel in vascular smooth muscle: relationship between KCa channel diversity and smooth muscle cell function. Circ. Res., 1999, 85, 33e.
4. Fanger, C.M.; Ghanshani, S.; Logsdon, N.J.; Rauer, H.; Kalman, K.; Zhou, J.; Beckingham, K.; Chandy, K.G.; Cahalan, M.D.; Aiyar, J. Calmodulin mediates calcium-dependent activation of the intermediate conductance channel, IKCa1. J. Biol. Chem., 1999, 274, 5746.
5. Wulff, H.; Kolski-Andreaco, A.; Sankaranarayanan, A.; Sabatier, J.M.; Shakkottai, V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr. Med. Chem., 2007, 14, 1437.
6. Kaczorowski, G.; Knaus, H.; Leonard, R.; McManus,O.; Garcia, M. High-conductance calcium-activated potassium channels; structure, pharmocology, and function. J. Bioenerg. Biomembr., 1996, 28(3), 255.
7. Ishii, T.M.; Silvia, C.; Hirschberg, B.; Bond, C.T.; Adelman, J.P.; Maylie, J. A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Sci. USA, 1997, 94, 11651.
8. Ca3.1 channel pore in relation to channel gating: results from a substituted cysteine accessibility analysis. J. Gen. Physiol., 2007, 129, 299.
9. 2+-activated K Channel. J. Gen. Physiol., 2006, 127, 159.
10. Jiang, Z.G.; Shi, X.R.; Guan, B.C.; Zhao, H.; Yang, Y.Q. Dihydropyridines inhibit acetylcholine-induced hyperpolarization in cochlear artery via blockade of intermediate-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther., 2007, 320, 544.
11. Alvarez, J.; Montero, M., Garcia-Sancho, J. High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J. Biol. Chem., 1992, 267, 11789.
12. De Franceschi, L.; Saadane, N.; Trudel, M.; Alper, S.; Brugnara, C.; Beuzard, Y. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J. Clin. Invest., 1994, 93(4), 1670.
13. + channel, IKCa1: a potential immunosuppressant. Proc. Natl. Acad. Sci. USA, 2000, 97, 8151.
14. + channels from human erythrocytes. J. Membr. Biol., 1998, 165(2), 133.
15. Rauer, H.; Pennington, M.; Cahalan, M.; Chandy, K.G. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem., 1999, 274, 21885.
16. Wulff, H.; Gutman, G.A.; Cahalan, M.D.; Chandy, K.G. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J. Biol. Chem., 2001, 276, 32040.
17. Manaves, V.; Qin, W.; Bauer, A.; Rossie, S.; Kobayashi, M.; Rane, S. Calcium and Vitamin D increase mRNA levels for the growth control hIK1 channel in human epidermal keratinocytes but functional channels are not observed. BMC Dermatol., 2004, 4, 7.
18. + conductance of human red cells as revealed by the patch-clamp technique. Cell. Calcium, 1983, 4(5-6), 499.
19. + channels in human mesenteric artery: a single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in Situ. Circ. Res., 2000, 87, 496.
20. Ghanshani, S.; Wulff, H.; Miller, M.J.; Rohm, H.; Neben, A.; Gutman, G.A.; Cahalan, M.D.; Chandy, K.G. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem., 2000, 275, 37137.
21. Kohler, R.; Wulff, H.; Eichler, I.; Kneifel, M.; Neumann, D.; Knorr, A.; Grgic, I.; Kampfe, D.; Si, H.; Wibawa, J.; Real, R.; Borner, K.; Brakemeier, S.; Orzechowski, H.D.; Reusch, H.P.; Paul, M.; Chandy, K.G.; Hoyer, J. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation, 2003, 108, 1119.
22. + channel (IKCa1) mediates phenotypic modulation of coronary smooth muscle. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H2493.
23. Cai, S.; Garneau, L.; Sauve, R. Single-channel characterization of the pharmacological properties of the K(Ca2+) channel of intermediate conductance in bovine aortic endothelial cells. J. Membr. Biol., 1998, 163(2), 147.
24. + channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis In Vivo. Arterioscler Thromb. Vasc. Biol., 2005, 25, 704.
25. Garland, C.J.; Plane, F. Relative importance of endothelium-derived hyperpolarizing factor for the relaxation of vascular smooth muscle in different arterial beds. Endothelium-Derived Hyperpolarizing Factor; Harwood Academic Publishers: Amsterdam, 1996, 173.
26. + channels directly control agonist-evoked nitric oxide synthesis in human vascular endothelial cells. Am. J. Physiol. Cell. Physiol., 2007, 293, C458.
27. Ca Channels. Reprod. Sci., 2007, 14, 43.
28. + channel in human endothelium. Cardiovasc. Res., 2003, 60, 488.
29. + Channel. Circ. Res., 2006, 99, 537.
30. van Bavel, E. Shear stress and intermediate-conductance calcium-activated potassium channels. Cardiovasc. Research., 2003, 60, 457.
31. Ca channels and caveolin-rich domains. Br. J. Pharmacol., 2007, 151, 332.
32. +-channel inhibitors in rat isolated mesenteric arteries. Br. J. Pharmacol., 2003, 138, 1031.
33. + channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery. J. Physiol., 2003, 553, 183.
34. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature, 1998, 396, 269.
35. + channels suppresses EDHF-mediated vasodilation. Br. J. Pharmacol., 2003, 138, 594.
36. + channel in porcine coronary endothelium: relevance to EDHF. Br. J. Pharmacol., 2002, 137, 1346.
37. Sainsbury, C.; Coleman, J.; Brady, A.; Connell, J.; Hillier, C.; Petrie, J. Endothelium-dependent relaxation is resistant to inhibition of nitric oxide synthesis, but sensitive to blockade of calcium-activated potassium channels in essential hypertension. J. Human Hypertens., 2007, 21, 808.
38. Ceroni, L.; Ellis, A.; Wiehler, W.B.; Jiang, Y.F.; Ding, H.;Triggle, C.R. Calcium-activated potassium channel and connexin expression in small mesenteric arteries from eNOS-deficient (eNOS-/-) and eNOS-expressing (eNOS+/+) mice. Eur. J. Pharmacol., 2007, 560, 193.
39. Fleming, I.; Busse, R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension, 2006, 47, 629.
40. Feletou, M.; Vanhoutte, P.M. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb. Vasc. Biol., 2006, 26, 1215.
41. Feletou, M.; Vanhoutte, P.M. EDHF: The complete story.Taylor & Francis, CRC press: Boca Raton, 2006, 1.
42. Busse, R.; Edwards, G.; Feletou, M.; Fleming, I.; Vanhoutte, P.M.; Weston, A.H. EDHF: bringing the concepts together. Trends Pharmacol Sci., 2002, 23, 374.
43. Shimokawa, H.; Yasutake, H.; Fujii, K.; Owada, M.; Nakaike, R.; Fukumoto, Y.; Takayanagi, T.; Nagao, T.; Egashira, K.; Fujishima, M.; Takeshita, A. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J. Cardiovasc. Pharmacol., 1996, 28(5), 703.
44. Sandow, S.L.; Neylon, C.B.; Chen, M.X.; Garland, C.J. Spatial separation of endothelial small- and intermediate-conductance calcium-activated potassium channels (KCa) and connexins: possible relationship to vasodilator function? J. Anat., 2006, 209, 689.
45. Neylon, C.B.; Avdonin, P.V.; Larsen, M.A.; Bobik, A. Rat aortic smooth muscle cells expressing charybdotoxin-sensitive potassium channels exhibit enhanced proliferative responses. Clin. Exp. Pharmacol. Physiol., 1994, 21, 117.
46. Neylon, C.B.; Avdonin, P.V.; Dilley, R.J.; Larsen, M.A.; Tkachuk, V.A.; Bobik, A. Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types. Circ. Res., 1994, 75, 733.
47. Owens, G.K.; Kumar, M.S.; Wamhoff, B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev., 2004, 84, 767.
48. Layne, M.D.; Yet, S.F.; Maemura, K.; Hsieh, C.M.; Liu, X.; Ith, B.; Lee, M.E.; Perrella, M.A. Characterization of the mouse aortic carboxypeptidase-like protein promoter reveals activity in differentiated and dedifferentiated vascular smooth muscle cells. Circ. Res., 2002, 90, 728.
49. Regan, C.P.; Adam, P.J.; Madsen, C.S.; Owens, G.K. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J. Clin. Invest., 2000, 106, 1139.
50. Bar, H.; Wende, P.; Watson, L.; Denger, S.; van Eys, G.; Kreuzer, J.; Jahn, L. Smoothelin is an indicator of reversible phenotype modulation of smooth muscle cells in balloon-injured rat carotid arteries. Basic Res. Cardiol., 2002, 97, 9.
51. Nagai, R.; Suzuki, T.; Aizawa, K.; Miyamoto,S., Amaki,T., Kawai-Kowase, K.K., Sekiguchi,K., Kurabayashi,M. Phenotypic modulation of vascular smooth muscle cells: dissection of transcriptional regulatory mechanisms. Ann. NY Acad. Sci., 2001, 947, 56.
52. Ratajska, A.; Zarska, M.; Quensel, C.; Kramer, J. Differentiation of the smooth muscle cell phenotypes during embryonic development of coronary vessels in the rat. Histochem. Cell. Biol., 2001, 116, 79.
53. Rensen, S.S.; Thijssen, V.L.; De Vries, C.J.; Doevendans, P.A.; Detera-Wadleigh, S.D.; van Eys, G.J. Expression of the smoothelin gene is mediated by alternative promoters. Cardiovasc. Res., 2002, 55, 850.
54. Stolle, K.; Weitkamp, B.; Rauterberg, J.; Lorkowski, S.; Cullen, P. Laser microdissection-based analysis of mRNA expression in human coronary arteries with intimal thickening. J. Histochem. Cytochem., 2004, 52, 1511.
55. van der Loop, F.T.L.; Gabbiani, G.; Kohnen, G.; Ramaekers, F.C.S.; van Eys, G.J. Differentiation of smooth muscle cells in human blood vessels as defined by smoothelin, a novel marker for the contractile phenotype. Arterioscler Thromb. Vasc. Biol., 1997, 17, 665.
56. van Eys, G.J.; Niessen, P.M.; Rensen, S.S. Smoothelin in vascular smooth muscle cells. Trends Cardiovasc. Med., 2007, 17, 26.
57. 2+ channels modulate expression of smooth muscle differentiation marker genes via a Rho Kinase/Myocardin/SRF-dependent mechanism. Circ. Res., 2004, 95, 406.
58. Wamhoff, B.R.; Bowles, D.K.; Owens, G.K. Excitation-transcription coupling in arterial smooth muscle. Circ. Res., 2006, 98, 868.
59. Ca3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb. Vasc. Biol., 2008, 28(6), 1084.
60. + channels and the microglial respiratory burst. Am. J. Physiol. Cell. Physiol., 2001, 280, C796.
61. + Channel expression during B cell differentiation: Implications for immunomodulation and autoimmunity. J. Immunol., 2004, 173, 776.
62. Pena, T.L.; Chen, S.H.; Konieczny, S.F.; Rane, S.G. Ras/MEK/ERK Up-regulation of the fibroblast KCa channel FIK Is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis. J. Biol. Chem., 2000, 275, 13677.
63. + channels in proliferating A7r5 vascular smooth muscle cells. Br. J. Pharmacol., 2006, 148, 909.
64. Wolfs, J.L.; Wielders, S.J.; Comfurius, P.; Lindhout, T.; Giddings, J.C.; Zwaal, R.F.; Bevers, E.M. Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood, 2006, 108, 2223.
65. Schneider, J.E.; Berk, B.C.; Gravanis, M.B.; Santoian, E.C.; Cipolla, G.D.; Tarazona, N.; Lassegue, B.; King, S.B., 3rd. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation, 1993, 88, 628.
66. Schwartz, R.S.; Murphy, J.G.; Edwards, W.D.; Camrud, A.R.; Vlietstra, R.E.; Holmes, D.R. Restenosis After Balloon Angioplasty - A practical proliferative model in porcine coronary arteries. Circulation, 1990, 82, 2190.
67. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993, 362, 801.
68. Barrett, T.B.; Benditt, E.P. Sis (platelet-derived growth factor B chain) gene transcript levels are elevated in human atherosclerotic lesions compared to normal artery. Proc. Natl. Acad. Sci. USA, 1987,84, 1099.
69. Holycross, B.J.; Blank, R.S.; Thompson, M.M.; Peach, M.J.; Owens, G.K. Platelet-derived growth factor-BB-induced suppression of smooth muscle cell differentiation. Circ. Res., 1992, 71, 1525.
70. Jawien, A.; Bowen-Pope, D.F.; Lindner, V.; Schwartz, S.M.; Clowes, A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest., 1992, 89, 507.
71. Yu, Y.; Sweeney, M.; Zhang, S.; Platoshyn, O.; Landsberg, J.; Rothman, A.; Yuan, J.X.J. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am. J. Physiol. Cell. Physiol., 2003, 284, C316.
72. Sano, H.; Sudo, T.; Yokode, M.; Murayama, T.; Kataoka, H.; Takakura, N.; Nishikawa, S.; Nishikawa, S.I.; Kita, T. Functional blockade of platelet-derived growth factor receptor-{beta} but not of receptor-{alpha} prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation, 2001, 103, 2955.
73. + channels regulate human airway smooth muscle proliferation. Am. J. Respir. Cell. Mol. Biol., 2007, 37(5), 525.
74. Angel, P., Karin, M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1991, 1072, 129.
75. Curran, T.; Franza, B.R., Jr. Fos and Jun: the AP-1 connection. Cell., 1988, 55, 395.
76. Cochran, B.H.; Zullo, J.; Verma, I.M.; Stiles, C.D. Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor. Science, 1984, 226, 1080.
77. Kruijer, W.; Cooper, J.A.; Hunter, T.; Verma, I.M. Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. Nature, 1984, 312, 711.
78. Franchimont, N.; Durant, D.; Rydziel, S.; Canalis, E. Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2. J. Biol. Chem., 1999, 274, 6783.
79. Zhan, Y.; Kim, S.; Yasumoto, H.; Namba, M.; Miyazaki, H.; Iwao, H. Effects of dominant-negative c-Jun on platelet-derived growth factor-induced vascular smooth muscle cell proliferation. Arterioscler Thromb. Vasc. Biol., 2002, 22, 82.
80. + channels in postischaemic heart. Clin. Exp. Pharmacol. Physiol., 2002, 29, 324.
81. Chong, J.A.; Tapia-Ramirez, J.; Kim, S.; Toledo-Aral, J.J.; Zheng, Y.; Boutros, M.C.; Altshuller, Y.M.; Frohman, M.A.; Kraner, S.D.; Mandel, G. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell, 1995, 80, 949.
82. Schoenherr, C.; Anderson, D. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron specific genes. Science, 1995, 267(5202), 1360.
83. Cheong, A.; Bingham, A.J.; Li, J.; Kumar, B.; Sukumar, P.; Munsch, C.; Buckley, N.J.; Neylon, C.B.; Porter, K.E.; Beech, D.J.; Wood, I.C. Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol. Cell, 2005, 20, 45.
84. Ooi, L.; Wood, I.C. Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet., 2007, 8, 544.
85. Cheong, A.; Wood, I.C.; Beech, D.J. Less REST, more vascular disease? Regulation of cell cycle and migration of vascular smooth muscle cells. Cell Cycle, 2006, 5(2), 129.
86. Koenigsberger, C.; Chicca, J.J., 2nd, Amoureux, M.C.; Edelman, G.M.; Jones, F.S. Differential regulation by multiple promoters of the gene encoding the neuron-restrictive silencer factor. Proc. Natl. Acad. Sci. USA, 2000, 97, 2291.
87. Brugnara, C.; Gee, B.; Armsby, C.C.; Kurth, S.; Sakamoto, M.; Rifai, N.; Alper, S.L.; Platt, O.S. Therapy with oral clotrimazole induces inhibition of the gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J. Clin. Invest., 1996, 97, 1227.
88. Brugnara, C.; De Franceschi, L. Clinical trials of new therapeutic pharmacology for sickle cell disease. Sante, 2006, 16(4), 263.
89. + channel modulators on human prostate cancer cell proliferation. Eur. J. Pharmacol., 2003, 471, 157.
90. + channels inhibit human pancreatic cancer cell growth in Vitro. Mol. Pharmacol., 2004, 65, 630.